Freestyle-Perimount Calcification Comparison

Sponsor
Ziekenhuis Oost-Limburg (Other)
Overall Status
Recruiting
CT.gov ID
NCT04359030
Collaborator
Universitaire Ziekenhuizen Leuven (Other)
90
1
10.5
8.6

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the rate and anatomy of the aortic wall and leaflet calcification of the FS prosthesis implanted as full root in patients younger than 60 years compared to a stented bioprostheses (Perimount Magna Ease, PM). A 3D CT scan will be used to assess the calcification score and to determine the relationship between calcification and aortic valve leaflet.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Multislice CT scanning for aortic wall calcification
  • Diagnostic Test: Transthoracic stress echocardiography

Detailed Description

A recent update of the American Hear Association and American College of Cardiology Guidelines for the Management of Patients With Valvular Heart Disease1 recommended that for patients between 50 and 70 years of age, it is reasonable to the choice of either a mechanical or bioprosthetic valve; the threshold for biological valves continues to decrease and more younger adults will receive this kind of prosthesis. However the best biological option for these patients is still a matter of debate. Stented bio-prosthesis is the most common choice. However, the predicted 15-year risk of needing reoperation because of structural deterioration is 22% for patients 50 years of age2.

In the late 80's stentless valve as the Medtronic Freestyle (FS) has been introduced with the hope that it may provide physiological flow in the aortic root, sinuses, and coronary orifices and a low risk of thromboembolism. Several randomized study and meta-analysis demonstrated improved hemodynamic, a larger orifice area and a midterm survival advantage of stentless aortic valve compared to stented aortic valve replacement3, 4. The FS valve is believed to provide greater durability and superior hemodynamic performance due to the low mechanical stress on the leaflet tissues. The failure mode of the FS is thought to be mostly calcification of the aorta wall and cusp tears because collagen degradation5. This phenomenon is inflammation mediated process.

Aim of this study is to evaluate the rate and anatomy of the aortic wall and leaflet calcification of the FS prosthesis implanted as full root in patients younger than 60 years compared to a stented bioprostheses (Perimount Magna Ease, PM). A 3D CT scan will be used to assess the calcification score and to determine the relationship between calcification and aortic valve leaflet.

Between 2007 and 2017, among patients younger than 60 years of age, 51 patients underwent a full root replacement with a FS and 49 received a Perimount Magna Ease prosthesis. Those patients will undergo a 3D CT scan. The group of the patient with PM will be matched in function of age and interval of follow-up with the FS group.

A transthoracic echocardiogram will be performed to check residual valve insufficiency and trans-valvular gradients. A cardiopulmonary exercise test ( with extraction of maximal oxygen consumption ) combined with a trans thoracic echocardiography (stress echocardiography) will be performed to evaluate the patients exercise capacity and its influence on the cardiac and valve function.

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
In Vivo Calcium Score Measurement After Freestyle Full Root Replacement in Young Adults
Actual Study Start Date :
Nov 15, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Oct 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Freestyle group

Patients treated with a Freestyle aortic valve bioprosthesis

Diagnostic Test: Multislice CT scanning for aortic wall calcification
Multislice CT scanning for aortic wall calcification

Diagnostic Test: Transthoracic stress echocardiography
Transthoracic stress echocardiography

Perimount group

Patients treated with a Perimount aortic valve bioprosthesis

Diagnostic Test: Multislice CT scanning for aortic wall calcification
Multislice CT scanning for aortic wall calcification

Diagnostic Test: Transthoracic stress echocardiography
Transthoracic stress echocardiography

Outcome Measures

Primary Outcome Measures

  1. Quantification of aortic leaflet Calcium-score in FS and PM valve [3 years]

    The Agatston score. The score is calculated using a weighted value assigned to the highest density of calcification in a given coronary artery. The density is measured in Hounsfield units (HU), and score of 1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 HU, and 4 for 400 HU and greater. The higher the score the more the calcification.

Secondary Outcome Measures

  1. Echocardiographic function of the aortic valve at rest and during exercise: transvalvular mean and peak gradient [3 years]

    Aortic valve mean and peak gradient: mmHg

  2. Echocardiographic function of the aortic valve at rest and during exercise: Valve regurgitation [3 years]

    Aortic valve regurgitation: vena contracta (mm)

  3. Exercise capacity: New York Heart Association class [3 years]

    New York Heart Association class from 1 to 4 with 1=no dyspnea during exercise till 4= dyspnea in rest;

  4. Exercise capacity: maximum oxygen consumption [3 years]

    max oxygen consumption measured in ml/kg*min

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 60 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Provision of signed and dated informed consent form

  • Patients treated with FS or PM

  • Age less than 60 at the moment of the implant

Exclusion Criteria:
  • Kidney failure or contrast allergy

  • Previous endocarditis and aortic dissection

  • Pregnancy or lactation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ziekenhuis Oost Limburg Genk Limburg Belgium 3600

Sponsors and Collaborators

  • Ziekenhuis Oost-Limburg
  • Universitaire Ziekenhuizen Leuven

Investigators

  • Principal Investigator: Matteo Pettinari, Ziekenhuis Oost-Limburg

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Matteo Pettinari, Principal Investigator, Ziekenhuis Oost-Limburg
ClinicalTrials.gov Identifier:
NCT04359030
Other Study ID Numbers:
  • ctu2020003
First Posted:
Apr 24, 2020
Last Update Posted:
Mar 2, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2022